Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia

British Journal of Haematology

Volumn 169, Issue 5, 2015, Pages 756-759

  Oshikawa, Gaku ^a   Kakihana, Kazuhiko ^a   Saito, Makoto ^a   Aoki, Jun ^a   Najima, Yuho ^a   Kobayashi, Takeshi ^a   Doki, Noriko ^a   Sakamaki, Hisashi ^a   Ohashi, Kazuteru ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Acute myeloid leukaemia; Allogeneic haematopoietic stem cell transplantation; Azacitidine; Gemtuzumab ozogamicin; Maintenance therapy

Indexed keywords

AZACITIDINE; GEMTUZUMAB OZOGAMICIN; AMINOGLYCOSIDE; ANTINEOPLASTIC AGENT; GEMTUZUMAB; MONOCLONAL ANTIBODY;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD LEVEL; BRAIN DISEASE; CANCER RISK; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HIGH RISK POPULATION; HUMAN; INFECTIOUS COMPLICATION; LETTER; LOW DRUG DOSE; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RELAPSE; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOID, ACUTE; MAINTENANCE CHEMOTHERAPY; PATHOLOGY; TREATMENT OUTCOME;

AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MAINTENANCE CHEMOTHERAPY; TREATMENT OUTCOME;

EID: 84929287043     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13248     Document Type: Letter

References (10)

1. Balaian, L. & Ball, E.D. (2006) Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk. Leukemia, 20, 2093-2101.
2. Choi, J., Ritchey, J., Prior, J.L., Holt, M., Shannon, W.D., Deych, E., Piwnica-Worms, D.R. & DiPersio, J.F. (2010) In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood, 116, 129-139.
3. de Lima, M., Giralt, S., Thall, P.F., de Padua Silva, L., Jones, R.B., Komanduri, K., Braun, T.M., Nguyen, H.Q., Champlin, R. & Garcia-Manero, G. (2010) Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer, 116, 5420-5431.
4. Linenberger, M.L., Hong, T., Flowers, D., Sievers, E.L., Gooley, T.A., Bennett, J.M., Berger, M.S., Leopold, L.H., Appelbaum, F.R. & Bernstein, I.D. (2001) Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood, 98, 988-994.
5. Mielcarek, M., Storer, B.E., Flowers, M.E., Storb, R., Sandmaier, B.M. & Martin, P.J. (2007) Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation, 13, 1160-1168.
6. Nand, S., Othus, M., Godwin, J.E., Willman, C.L., Norwood, T.H., Howard, D.S., Coutre, S.E., Erba, H.P. & Appelbaum, F.R. (2013) A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. Blood, 122, 3432-3439.
7. Pinto, A., Attadia, V., Fusco, A., Ferrara, F., Spada, O.A. & Di Fiore, P.P. (1984) 5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood, 64, 922-929.
8. Sanchez-Abarca, L.I., Gutierrez-Cosio, S., Santamaria, C., Caballero-Velazquez, T., Blanco, B., Herrero-Sanchez, C., Garcia, J.L., Carrancio, S., Hernandez-Campo, P., Gonzalez, F.J., Flores, T., Ciudad, L., Ballestar, E., Del Canizo, C., San Miguel, J.F. & Perez-Simon, J.A. (2010) Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood, 115, 107-121.
9. Schmid, C., Labopin, M., Nagler, A., Niederwieser, D., Castagna, L., Tabrizi, R., Stadler, M., Kuball, J., Cornelissen, J., Vorlicek, J., Socie, G., Falda, M., Vindelov, L., Ljungman, P., Jackson, G., Kroger, N., Rank, A., Polge, E., Rocha, V., Mohty, M. & Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). (2012) Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood, 119, 1599-1606.
10. Watanabe, K., Doki, N., Miura, Y., Hagino, T., Kurosawa, S., Hino, Y., Shingai, N., Yoshioka, K., Ishida, S., Igarashi, A., Najima, Y., Kobayashi, T., Kakihana, K., Sakamaki, H. & Ohashi, K. (2014) Toxic encephalopathy after exposure to azacitidine. Leukaemia & Lymphoma, doi:10.3109/10428194.2014.964701, Epub ahead of print